Status:
UNKNOWN
Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma
Lead Sponsor:
Hamilton Health Sciences Corporation
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multiple Myeloma is an incurable cancer. Therapies for it include oral chemotherapy pills. It is unknown whether patients regularly and correctly take these anti-myeloma pills. This study wants to mea...
Detailed Description
The prevalence of patients with myeloma utilizing orally-administered myeloma therapy (OMT) is expected to continuously rise within Canada. The MASCC Oral agent Teaching Tool (MOATT) interventional to...
Eligibility Criteria
Inclusion
- Will include adults (age\>18) with multiple myeloma who will be initiating OMT (lenalidomide or pomalidomide in the next 6 months) for either newly diagnosed, maintenance-phase or relapsed myeloma at the JCC
Exclusion
- Patients who reside in a facility in which their medications are administered to them (such as a nursing home)
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04376957
Start Date
August 1 2020
End Date
February 1 2022
Last Update
May 6 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.